The effect of intravenous iron on postoperative transfusion requirements in hip fracture patients: study protocol for a randomized controlled trial by Rowlands, Martin et al.
TRIALS
Rowlands et al. Trials 2013, 14:288
http://www.trialsjournal.com/content/14/1/288STUDY PROTOCOL Open AccessThe effect of intravenous iron on postoperative
transfusion requirements in hip fracture patients:
study protocol for a randomized controlled trial
Martin Rowlands1, Daren P Forward2, Opinder Sahota3 and Iain K Moppett1*Abstract
Background: Anaemia following hip fracture is common. Approximately 30 to 45% of patients have haemoglobin
concentrations below population norms on admission, and around 10% are severely anaemic. Anaemia on
admission, and in the postoperative period, is associated with poor outcomes with regard to mobility,
postoperative mortality and readmission. There is currently no clear consensus on the optimal method of managing
perioperative anaemia in this group of frail patients with frequent comorbidity. Liberal red cell transfusion in the
postoperative period does not appear to improve outcome, whereas tranexamic acid appears to reduce transfusion
rate at the expense of increased cardiovascular morbidity. There are encouraging results from one centre with the
use of agents to stimulate red cell production, including intravenous iron and erythropoietin. UK practice differs
significantly from these patients and these studies, and it is not clear whether these promising results will translate
to the UK population.
Methods/Design: This is a single-centre randomized controlled parallel group trial, in a British university hospital.
Randomization is achieved using a website and computer-generated concealed tables. Participants are 80 patients
70 years or over with acute hip fracture undergoing operative repair. The intervention group receive three daily
infusions of 200 mg iron sucrose, starting within 24 hours of admission. The control group receive standard hospital
care at the discretion of the clinical team. Red cell transfusions for each group are given in accordance with
standard clinical triggers. The primary outcome is an increase in mean reticulocyte count in the intervention group
at day 7. Secondary outcome measures include haemoglobin concentrations, early and late transfusion rates,
infectious and cardiovascular complications, mobility and 30-day mortality.
Discussion: This is a pilot study to demonstrate haematopoietic efficacy of intravenous iron in this setting. Hence,
we have chosen to measure change in reticulocyte count rather than the more clinically relevant differences in
haemoglobin concentration or transfusion rate. If our results are positive, the study will provide the necessary
information for development of a full-scale trial of intravenous iron.
Trial registration: Current Controlled Trials ISRCTN76424792; UK Medicines and Healthcare products Regulatory
Authority (EuDRACT: 2011-003233-34).
Keywords: Aged 70 and over, Anaemia: iron deficiency, Anaemia: therapy, Ferric compounds: administration and
dosage, Ferric compounds: therapeutic use, Hip fractures: surgery, Human beings, Perioperative period,
Postoperative complications: drug therapy* Correspondence: iain.moppett@nottingham.ac.uk
1Division of Anaesthesia and Intensive Care, University of Nottingham,
Nottingham, UK
Full list of author information is available at the end of the article
© 2013 Rowlands et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Rowlands et al. Trials 2013, 14:288 Page 2 of 8
http://www.trialsjournal.com/content/14/1/288Background
Anaemia following hip fracture is common. Approxi-
mately 30 to 45% of patients have haemoglobin concen-
trations ([Hb]) below population norms on admission
and around 10% are severely anaemic. The average fall
in [Hb] between admission and postoperative nadir is
around 2 g/dl. Various authors [1-4] have found [Hb] on
admission to be an independent risk factor for early [1,2]
and late [3] postoperative mortality. Foss and colleagues
[5] found postoperative [Hb] < 10 g/dl to be an inde-
pendent risk factor for poor mobility in previously mo-
bile patients, whilst Lawrence and colleagues [6] found
that walking distance was strongly correlated with [Hb]
> 10 g/dl. In healthy older people, mobility is better in
individuals with [Hb] > 12 g/dl [7]. Health outcomes in
the general older population are worse in the presence
of anaemia [8].
Anaemia in the older hip fracture population is multi-
factorial. Ageing per se does not appear to cause an-
aemia [9], but ageing may be associated with reduced
haematopoietic reserve, making anaemia more likely in
the face of nutrient deficiency or blood loss [10]. In the
community, 20% of women aged 80 to 85 are anaemic,
with anaemia of chronic disease being the most common
cause. These patients represent a major proportion of
the hip fracture population. However, 30 to 45% of hip
fracture patients are anaemic on admission [11], which
may reflect frailer patients having poorer nutrition, being
more likely to sustain hip fractures and subsequently
having their [Hb] fall further, owing to acute fracture-
related blood loss.
Pre-existing anaemia on admission is further exacer-
bated by the effects of intravenous rehydration, and
small but significant intra-operative blood loss results in
between one-third and two-thirds of patients receiving
blood transfusions within the first few days following op-
eration [5]. The likelihood of transfusion is related to
fracture type: subtrochanteric and trochanteric fractures
have the highest transfusion rates in both anaemic and
nonanaemic subjects. Poor nutrition in the postoperative
period is also unlikely to replenish iron stores. Surgery
itself may further induce a functional iron deficiency due
to humoral suppression of erythropoiesis [12]. Func-
tional iron deficiency does not respond well to oral iron,
as iron stores may be normal, and this suppresses intes-
tinal absorption of iron. Indeed, postoperative oral iron
has been shown to be of no benefit and also has a high
incidence of side effects [13]. Whereas blood transfusion
improves [Hb], some authors have found an association
between transfusion and improved mobility [5]; others
have not found this association, but found that transfu-
sion might reduce readmission rates [14]. Infection rates
may also be increased with the use of blood transfusion
[15] and there are significant financial constraints withthe current cost of a unit of blood in the UK around
£200. A recently reported North American trial assessed
the effects of liberal versus restrictive postoperative
transfusion strategies following hip fracture in patients
with cardiovascular risk factors [16-18]. That study
found no differences in self-reported mobility or death
at 60 days, though there was an increase in cardiovascu-
lar complications in the restrictive group. It would seem
therefore, at this time that anaemia is a poor prognostic
factor but that red cell transfusion does not necessarily
alter outcome.
Alternatives to blood transfusion include reduction in
blood loss in the perioperative period; stimulation of
erythropoiesis with erythropoietin; and oral or intraven-
ous iron.
Pharmacological reduction of blood loss with tranex-
amic acid has been assessed recently [19]. Although
there was a trend to reduced transfusion requirements
and reduced postoperative infections, there was also a
trend towards increased thrombotic events in the trane-
xamic acid group and it is therefore not a recommended
therapy in this group, despite being advocated for patients
with multiple traumas [20].
Erythropoietin has been used in older people to stimu-
late erythropoiesis. However, the side effects of erythro-
poietin (hypertension, risks of thrombotic events) make
it unattractive in the hip fracture population and the
cost of erythropoietin used in these studies is high, over
£200 per patient.
Intravenous iron is an attractive therapy in this popu-
lation. Intravenous iron bypasses the intestinal barrier to
absorption [21] that may be seen in functional iron defi-
ciency and stimulates erythropoiesis. The effects of i.v.
iron are believed to last for around 7 days, which covers
the at-risk period for patients with hip fracture. In post-
partum women, who commonly have moderate blood
loss during delivery, i.v. iron has been shown to have a
faster effect on [Hb] than oral iron [22]. Intravenous
iron is believed to be much less likely to cause adverse
reactions than in the past, following changes in its
pharmaceutical preparation. Iron sucrose is associated
with the lowest rate of life-threatening adverse events of
all the i.v. iron preparations and these are considerably
lower than transfusion-related severe side effects (0.11/
million versus 10/million) [23]. Four studies from a
Spanish group have reported the effects of i.v. iron on
transfusion requirements, mortality and outcome com-
pared with historical controls [21]. Cuenca and col-
leagues [24] reported a nonsignificant reduction in
transfusion rate in patients with trochanteric fractures
(55% vs. 44%). A prespecified subgroup of patients with
[Hb] >12 demonstrated a significant reduction in trans-
fusion rate (41% vs. 26%). In another retrospective study,
transfusion rates were halved (37% vs. 15%) as were the
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and 30 day mortality [21]. In a parallel group study [25],
transfusion rates were also more than halved (70% vs.
24%) as were the number of units transfused and post-
operative infection rates. Recently, the same group have
reported on a randomized controlled trial of intravenous
iron therapy [26]. No difference was found in transfusion
rates for the trial as a whole, but prespecified subgroup
analysis demonstrated a reduction in transfusion re-
quirements for patients with subcapital fractures and
those admitted with [Hb] > 12 g/dl. Overall there is a re-
duction in both red cell transfusion and postoperative
infection of around 40%; 30-day mortality and length of
stay do not appear to be altered. Laboratory data sup-
port the positive effects of i.v. iron on erythropoiesis
with statistically and clinically significant increases in re-
ticulocyte counts and iron indices. These data used non-
randomized comparison groups, except for the final
study. Furthermore, clinical management is different
from current UK practice and guidelines, with an ave-
rage time to theatre of over 4 days, compared with a UK
median time of around 48 hours [27]. Recent changes to
UK tariffs strongly encourage operation within 36 hours
[28,29].
Intravenous iron therapy is relatively inexpensive; 200
mg of iron sucrose costs around £15. Administration
costs for i.v. iron are likely to be similar to blood trans-
fusion, in terms of consumables and nursing time. Even
if the only benefit of intravenous iron is to reduce trans-
fusion rates, the potential cost savings are considerable.
Potential benefits, such as a reduction in infectious com-
plications, which are suggested by the current literature,
would result in significant cost savings to the healthcare
economy, as well as improved quality of care. The direct
consumable costs are probably slightly in favour of i.v.
iron. With an estimated i.v. iron cost of £43 and blood
unit cost of £200, assuming that an average of two units
are transfused when given, if i.v. iron reduces transfusion
rates from 38% to 25%, the direct cost saving in
transfusion-related costs is around £10 per patient. Un-
like cost savings from length of stay, these are direct sa-
vings to the healthcare system that can be realised, as
well as releasing a scarce resource for use elsewhere.
The current literature supports the hypothesis that i.v.
iron might be an effective and safe treatment, reducing
the need for blood transfusion following hip fracture.
Given the differences between UK and Spanish hip frac-
ture management, particularly regarding time to ope-
ration, it is unclear whether the promising results from
the Spanish experience will be applicable to the UK hip
fracture population. It is unknown at present whether
i.v. iron would have sufficient erythropoietic effect in hip
fracture patients to reduce transfusion rates in the early
postoperative period.A large randomized controlled trial of preoperative i.v.
iron for patients with hip fracture may be appropriate.
To inform appropriate design of such a trial, a pilot
study evaluating the haematological effect of i.v. iron in
this population is required.
Methods/Design
Study objectives
Primary aims
To investigate whether intravenous iron given as three
200 mg doses over three days in patients with hip frac-
ture causes an increase in reticulocyte count in the early
postoperative period;
Secondary aims
To discover whether intravenous iron has beneficial ef-
fects on other measures of haematopoiesis, transfusion
requirements and patient outcomes.
Haematological measures
As haematopoietic indices, full blood count and serum
transferrin receptor concentrations will be measured.
These will be collected daily for 7 days following admis-
sion. In addition, the number of patients requiring blood
transfusion during hospital admission and the transfu-
sion index (units/patient) will be determined.
Patient outcome measures
A number of patient outcomes will be measured: postop-
erative infectious complications, cardiovascular complica-
tions, and the length of acute hospital stay. In addition
functional mobility at days 1 to 3 will be assessed using a
cumulated ambulation score. Transfusion-related costs
(consumables and nursing time) will be determined, and
overall acute healthcare costs will be estimated from
length of stay, investigations and drug costs.
Study design
This is a prospective, single-centre, randomized, parallel
group controlled trial conducted at the Queen’s Medical
Centre campus of Nottingham University Hospitals,
Nottingham, UK. Study recruitment commenced in July
2012 when the first patient was randomized. Recruit-
ment is expected to take 24 months.
Randomization and blinding
Randomization (on a one-to-one allocation basis) is via a
password-protected web-based randomization service
provided by the Clinical Trials Support Unit and the se-
quence is not revealed until datalock. Participants are
randomized within 24 hours of admission, either before
or after surgery.
The treating team, research nurse collecting data and
research team analyzing data will be blinded to treatment
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allocation. The patient and ward nursing staff will not be
blinded, for practical reasons (Venofer is a dark brown,
aqueous solution). There is no placebo.
Postoperative data collection is by a research nurse
blinded to treatment allocation. The decision that a pa-
tient is medically fit for discharge is made by the
multiprofessional team, when all are satisfied that the
participant has no ongoing needs for acute hospital care.
This team is blinded to participant allocation.
Selection and withdrawal of participants
Recruitment
Participants are identified by their presence on surgical
lists and are recruited from the trauma wards. The in-
vestigator informs the participant or the participant’s
nominated representative (other individual or other body
with appropriate jurisdiction), of all aspects pertaining to
participation in the study. Active participation in the
study is for the first seven days of hospital admission. The
study intervention is complete after the third day (admi-
nistration of i.v. iron) with daily blood tests until day 7.
The medical notes are reviewed following hospital dis-
charge for in-hospital complications and medication use.
Participants are informed that entry into the trial is
voluntary and that they are free to withdraw at any
time without effect on subsequent care. Data on time
to discharge and postoperative mortality are collected
routinely and separately from this study. These out-
come data are therefore available for all randomized
participants.
Patients who are unable to provide consent for them-
selves are not included in this study, owing to its pilot
nature and the off-label use of intravenous iron.
Patients for whom language may be a barrier are eli-
gible for inclusion to the study using standard
interpreting services. In practice, this is a very small pro-
portion of the total older population in the study centre.
Inclusion criteria
Patients listed for or having undergone surgical repair of
fractured neck of femur, who are aged 70 years or over
and are admitted directly to the study centre through
the emergency department will be included.
Exclusion criteria
Participants will be excluded if they have had an
undisplaced intracapsular fracture (as this requires a very
low transfusion rate), or if there are any of the following
contra-indications to intravenous iron therapy:
 Severe infection on admission.
 Liver disease.
 Known sensitivity to intravenous iron.Participants taking iron orally will be excluded, as the
simultaneous use of oral iron is prohibited in accordance
with the licensing of Venofer (although taking oral iron
prior to admission is not).
Participants will also be excluded if they are currently
taking clopidogrel or ticlopidine (local practice is not
to delay surgery for patients taking clopidogrel or
ticlopidine, but they are at increased risk of bleeding
in the intra-operative and perioperative period);
aspirin is not an exclusion medication. (UK doses
(75 mg or 150 mg) are not associated with increased
surgical bleeding).Informed consent
The capacity for providing consent is assessed routinely
by the orthopaedic team, who decide whether the pa-
tient is competent to provide consent for the surgical
procedure. If the orthopaedic team deem the patient
unable to consent to their surgery, then the patient
will be deemed incapable of consenting to enter the
study. A member of the research team also performs
an additional check of the participant’s ability to pro-
vide consent, immediately prior to starting the study.
All members of the research team are trained at
obtaining consent in accordance with guidance for
good clinical practice [30].Study intervention
Investigation medical product administration
Patients allocated to the investigation medical product
will receive 200 mg iron sucrose (Venofer) on three
separate occasions. T1 will be day 1 (within 24 hours of
admission); T2 will be day 1 after the operation, or the
second morning following admission if the patient has
not yet gone to theatre; T3 will be day 2 after the ope-
ration, or the third morning following admission if the
patient has not yet gone to theatre.
Administration of intravenous iron will be in accor-
dance with manufacturer’s recommendations. 10 ml
Venofer (200 mg iron) will be diluted in 100 mls 0.9%
sodium chloride for injections (to give a final concentra-
tion of 2 mg/ml).
On the first occasion, the first 25 mg of iron (i.e. 12.5
ml of solution) will be infused as a test dose over a
period of 15 minutes. If no adverse reactions occur du-
ring this time then the remaining portion of the infusion
will be given at an infusion rate of 100 mls/hour.
Oral iron is prohibited for at least 5 days following
administration of intravenous iron. Given the negative
results of a recent study of oral iron in hip fracture
[13], oral iron will not be permitted for any study par-
ticipants until day 10.
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Analgesia will be provided in accordance with normal
practice at the study centre. Nonsteroidal anti-inflamma-
tory drugs are not prescribed routinely to this group of
patients, and will be prohibited for patients in the study.
Other medication will be prescribed by the attending
medical staff as appropriate for each individual.
Concomitant treatments
Physiotherapy, surgery and anaesthesia will be adminis-
tered in accordance with normal clinical practice during
the trial.
Laboratory analyses
Blood samples will be taken from the participants on ad-
mission, and once each on days 1 to 7 following admis-
sion. Where possible, these blood samples will be taken
at the same time as clinically required samples, to re-
duce the participants’ discomfort. Analysis will be car-
ried out in the hospital’s haematology laboratory using
standard techniques. This laboratory is certified in ac-
cordance with National Health Service standards, and
undergoes its own quality assurance programme. Sam-
ples will be destroyed in accordance with normal pro-
cedures once analyzed, in accordance with the UK
Human Tissue Act, 2006.
Standard care
Standard care will be identical in both groups; only the ad-
ministration of interventional medical product will differ.
All patients are admitted to dedicated trauma wards
and cared for in accordance with UK ‘Best Practice
Tariff ’ [29]. This includes assessment by orthogeriatricians;
operation within 36 hours of admission; and assessment of
bone health and falls. All patients are cared for under a
hip fracture care pathway, which involves rapid assess-
ment and admission from the emergency department;
intravenous crystalloid infusions from the time of ad-
mission and multiprofessional care and discharge plan-
ning. Operations are performed in dedicated trauma
theatres by consultants in anaesthesia and orthopaedic
trauma or senior trainees. The Queen’s Medical Centre
has undertaken continuous, systematic audit of its hip
fracture care since 2011 [4,11,31].
Transfusion triggers
Perioperative transfusion will be at the discretion of the
attending anaesthetist. Transfusion following return to
the ward will be at the discretion of the ward team. In-
dications for transfusion are, in order of clinical priority:
 Ongoing blood loss with hypovolaemia;
 Symptomatic anaemia: anaemia with haemoglobin
concentration < 10 g/dl associated with persistenthypotension, angina, heart failure or cerebral
dysfunction;
 Asymptomatic anaemia with haemoglobin
concentration < 8 g/dl;
 Relative anaemia ([Hb] significantly less than normal
for the patient) and poor functional recovery.
Cost analysis
Data on the cost of treatment will be calculated from
drug use, investigations (diagnostic imaging, electro-
cardiography, blood testing) and the clinical record.
This includes standardized costs for physiotherapy,
occupational therapy and discharge planning. The
cost of additional monitoring required for each pa-
tient will also be taken into consideration. Data will
be presented in terms of total nonoperative costs,
costs per day and excess costs attributable to treat-
ment group.
Statistics
Data will be analyzed by the research team in con-
junction with a medical statistician, using the latest
version of SPSS software. There will be no interim
analysis.
The primary outcome measure, difference in mean re-
ticulocyte count between groups in the full analysis set
will be analyzed using unpaired t tests or Mann-Witney
tests as appropriate. Differences between groups in max-
imal change in [Hb], serum transferrin concentration,
postoperative mobility, number of units transfused and
estimated costs will similarly be analyzed.
Risk ratios will be described for categorical data: the
number of patients in each group with cardiovascular or
infective complications; and the number of patients re-
quiring transfusion. Descriptive statistics will be used to
summarise length of stay and 30-day mortality.
Prespecified subgroup analysis will be undertaken
according to admission haemoglobin concentrations
([Hb] <12 or >12 g/dl) and fracture type (sub-trochanteric,
extracapsular, intracapsular, pathological).
In addition to the calculated values, confidence inter-
vals and odds- ratios will be presented when appropriate.
All clinical information including all adverse events will
be presented in full. All secondary analyses will be
interpreted with caution as the sample size calculation is
based on the primary outcomes only. However, the level
of power associated with secondary results will be
investigated.
Sample size and justification
We propose to study a convenient sample size, with 40
participants in each group. Groups of 35 participants
each would provide a statistical power of 80% for finding
an absolute difference in maximum reticulocyte count of
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1.6%. This would also provide a statistical power of 80%
for finding a difference in serum transferrin receptor
concentration of 0.33 mg/dl. This is a conservative esti-
mate of effect size; Garcia-Erce et al. [25] found diffe-
rences of 1.75% and 0.4 mg/dl respectively. The extra
ten patients are included to account for drop-outs.
Definition of datasets analyzed
The safety set will comprise all randomized partici-
pants who receive at least one dose of the study drug
or are randomized to standard care. The full analysis
set will comprise all randomized participants for whom
at least initial and day 7 reticulocyte counts are avai-
lable. The per-protocol set will comprise all partici-
pants in the full analysis set who are deemed to have
no major protocol violations that could interfere with
the objectives of the study. Safety summaries will be
performed on the safety set.
Reporting of adverse events
All adverse events will be recorded and closely moni-
tored until resolution or stabilisation, or until it has been
shown that the study treatment is not the cause. Partici-
pants will be asked to contact the study site immediately
in the event of any serious adverse event. The chief
investigator shall be informed immediately of any serious
adverse events and shall determine seriousness and
causality in conjunction with any treating medical
practitioners.
All treatment-related serious adverse events will be
recorded and reported to the research ethics committee
as part of the annual reports. Unexpected serious ad-
verse events will be reported to the research ethics com-
mittee and the sponsor within the relevant timeframes.
The chief investigator shall be responsible for all adverse
event reporting.
Ethics committee and regulatory approval
The trial will be conducted in accordance with ethical
principles that have their origin in the Declaration of
Helsinki, 1996 [32]; principles of good clinical practice
[30], and the Department of Health Research Gover-
nance Framework for Health and Social Care, 2005 [33].
Potential conflicts of interest
The manufacturer of Venofer has had no involvement in
design or funding of this study. All drugs are being pur-
chased from the company at normal prices.
Discussion
Anaemia following hip fracture is common and associ-
ated with poorer outcomes for this group of frail pa-
tients. However, the optimal treatment for it is not yetknown. Blood loss at the time of injury is not amenable
to intervention, so therapeutic choices include minimi-
zing further blood loss through surgical, anaesthetic and
pharmacological techniques, encouraging haematopoiesis
or replacing blood by transfusion. Tranexamic acid, an
anti-fibrinolytic agent, has been shown to be beneficial
in elective orthopaedic surgery [19,20] and in major
trauma. In hip fracture patients, however, it appears to
reduce blood loss at the cost of increased cardiovascu-
lar morbidity [19]. The impact of blood transfusion on
outcomes remains controversial. Some studies support
a risk of infective complications from transfusion [15]
whereas others have found benefit from transfusion
[5,14]. The recently reported FOCUS study found no
overall benefit from liberal vs. restrictive transfusion po-
licies [18]. One explanation for these results may be that
the risks of blood transfusion broadly balance out the
benefits. An alternative approach is therefore to encou-
rage haematopoiesis thereby improving [Hb] without the
attendant risks and costs of transfusion. Although the
results from the Spanish group are very encouraging,
they are not, in themselves, sufficient to recommend rou-
tine use of intravenous iron or erythropoietin in this
group of patients. The subgroups showing benefit in each
of the studies are different, as is the drug protocol. The
time to surgery is significantly longer than UK or Scandi-
navian practice, which may, potentially, have significant
impact on perioperative transfusion requirements. We
have explicitly defined our subgroups a priori. This study
is not powered to detect differences in these subgroups,
but these subgroups are broadly in line with those where
differences in efficacy of i.v. iron have previously been
reported. A-priori subgroup analysis may provide sug-
gestive evidence for planning future studies. As with all
clinical studies, we have tried to balance pragmatism,
generalizability and scientific ‘purity’ in the protocol.
We have excluded patients under 70 years of age to re-
duce the risks of studying a population that is younger
and fitter than the ‘average’ hip fracture patient. Our
transfusion triggers are a codification of current clinical
practice, which broadly reflect UK clinical practice.
Inevitably, they will not precisely match practice
across the UK or worldwide, but we believe they are
similar enough to be applicable elsewhere. On the
\basis of current evidence, we do not feel that there is
sufficient evidence to either proscribe or demand the
use of tranexamic acid. Our local practice is not to delay
surgery for patients on clopidogrel or ticlopidine, but
they are at increased risk of bleeding in the intra-
operative and perioperative period; such patients are
therefore excluded from the study. Standard care is
similar to most units in the UK, and the randomization
process should account for any potential bias due to diffe-
rences in local practice.
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vention, will alter major outcomes, such as length of
stay, mortality or readmission rates to a clinically signifi-
cant degree, but it is plausible for it to have a beneficial
effect on transfusion rates. However, this is only likely to
happen if a significant effect on erythropoiesis occurs;
hence, our choice of the absolute difference in reticulo-
cyte count as the primary outcome of this study. We
have chosen day seven as the primary time point for
measuring difference in reticulocyte count. Although
an effect may be seen at later times, we believe, con-
sistent with the literature [25], that if a clinically sig-
nificant effect is present, it will be observed within one
week. Prolonging the observation time also risks losing
participants due to discharge.
If the results of this study are positive, it will pro-
vide the necessary information for development of a
full-scale trial of intravenous iron. There is an in-
creasing awareness of the benefit of bundles of care
[34] as opposed to single ‘magic bullet’ interventions
[35] to improve outcomes following surgery. A full-
scale trial would help to define the potential cost, re-
source requirement (blood products) or direct patient
benefit of using intravenous iron as part of such a
bundle of care. If there is a cost benefit to using
intravenous iron, this could be significant: around
80,000 patients have operative fixation of hip fracture in
the UK each year [36]. Conversely, if there is no benefit
in the UK setting, then healthcare resources could
usefully be directed elsewhere.Trial status
Approvals were obtained from the Nottingham Research
Ethics Committee on 23 November 2011 (reference
number 11/EM/0310), the Nottingham University Hos-
pitals Research and Development department on 2
August 2011 (reference number 68213) and the UK
Medicines and Healthcare products Regulatory Author-
ity on 19 January 2012, (EuDRACT: 2011-003233-34).
The study was also registered with the National Institute
for Health Research Portfolio and ISRCTN:76424792 (10
September 2012). The study is ongoing. The first partici-
pant was randomized on 19 July 2012; it is hoped that
the study will be completed with the last visit of the last
patient before 12 March 2014.Abbreviations
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